Last updated: 2026-09-09 04:54:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
TransMedics Group, Inc. (TMDX) operates in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $88.23, with a market capitalization of $3.12B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $60.11 to $156.00. This page covers its latest market performance, valuation, price trends and company information.
$3.12B | |
$89.14 | |
$177.37 | |
$10.00 | |
$89.98 | |
415.86K | |
936.49K | |
-- | |
$156.00 | |
$60.11 | |
-- | |
-- |
TransMedics Group, Inc. (TMDX) last closed at $89.98 as of 2026-09-08 23:31:00, unchanged from the previous close of $89.98.
During the latest regular trading session, TMDX traded between $10.00 and $177.37, with a volume of 415.86K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, TransMedics Group, Inc. (TMDX) moved from $91.75 to $88.23, representing a decline of 3.84% ($3.52).
The stock traded between $81.34 and $94.24 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 689.50 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 29.3%
TMDX is currently trading at $88.23, placing it 29.3% of the way from its 52-week low of $60.11 to its 52-week high of $156.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
| Industry | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
| Employees | 898 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of TransMedics Group, Inc. (TMDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.